Synaptopathy

Pipeline Therapeutics to Present at the Jefferies Virtual Global Healthcare Conference

Retrieved on: 
Thursday, May 28, 2020
Biotechnology, General Health, Pharmaceutical, Health, Branches of biology, Organ systems, Neurophysiology, Neuroregeneration, Nervous system, Axon, Synaptopathy, Sensorineural hearing loss

Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced that Carmine Stengone, President and Chief Executive Officer, will present at the Jefferies Virtual Global Healthcare Conference on Thu, Jun 4, 2020 at 3:00 p.m.

Key Points: 
  • Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced that Carmine Stengone, President and Chief Executive Officer, will present at the Jefferies Virtual Global Healthcare Conference on Thu, Jun 4, 2020 at 3:00 p.m.
  • Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair.
  • The companys lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor (GSI) to treat mild-to-moderate sensorineural hearing loss (SNHL) associated with cochlear synaptopathy.
  • The company also has a portfolio of programs, including PIPE-307, focused on remyelination and axonal repair, to address a range of neurological disorders, including multiple sclerosis.

Pipeline Therapeutics to Participate in the 19th Annual Needham Virtual Healthcare Conference

Retrieved on: 
Thursday, April 9, 2020
Biotechnology, Pharmaceutical, Health, Neurophysiology, Neuroregeneration, Axon, Synaptopathy, Biology

Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced that the company will participate in the 19th Annual Needham Virtual Healthcare Conference, a fully virtual management access conference, taking place April 14-15.

Key Points: 
  • Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced that the company will participate in the 19th Annual Needham Virtual Healthcare Conference, a fully virtual management access conference, taking place April 14-15.
  • Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair.
  • The companys lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor (GSI) to treat mild-to-moderate sensorineural hearing loss (SNHL) associated with cochlear synaptopathy.
  • The company also has a portfolio of programs, including PIPE-307, focused on remyelination and axonal repair, to address a range of neurological disorders, including multiple sclerosis.